Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743244 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT05743244 is a Phase 2 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 78 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05743244, a Phase 2 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ritlecitinib
- DRUG Abrocitinib 200 MG Oral Tablet
Study Locations (20)
California
- Children's Hospital Orange County - Orange
- Stanford University - Palo Alto
- University of California- San Francisco - San Francisco
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- University of South Florida Diabetes Center - Tampa
New York
- UBMD Pediatrics - Buffalo
- Columbia University-Naomi Berrie Diabetes Center - New York
- Joslin Center at SUNY Upsate - Syracuse
Colorado
- Barbara Davis Center at University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory Children's Center - Atlanta
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743244
The ClinicalTrials.gov registry entry for NCT05743244 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05743244 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05743244 about?
NCT05743244 is a clinical study titled "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)". A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
What is the current status of trial NCT05743244?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2023-10-19. Estimated completion is 2027-06-30.
What conditions does trial NCT05743244 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05743244?
The interventions under investigation include: Placebo (DRUG), Ritlecitinib (DRUG), Abrocitinib 200 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05743244?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743244 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
-
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.